Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04740047
Other study ID # 20-004757
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date February 1, 2021
Est. completion date May 2024

Study information

Verified date March 2024
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Evaluate the clinical utility and early performance of the Cios 3D Mobile Spin in conjunction with the Ion Endoluminal System, to visualize and facilitate the sampling of pulmonary nodules between 1-3 cm via the airway.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 30
Est. completion date May 2024
Est. primary completion date November 4, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject age 18 years and older - Subject is suitable for elective bronchoscopy - Subject with a moderate to high risk of lung cancer based on clinical, demographic and radiologic information or with suspected metastatic disease - Solid or semi-solid pulmonary nodules of = 1cm and =3.5 cm in largest dimension - Nodule is located in bronchial generation 4+ (i.e. beyond segmental bronchus) - Subject is a candidate for CT-guided needle biopsy - Subject is able to understand and adhere to study requirements - Subject is able to understand and adhere to study requirements and able to provide informed consent - Subject is not legally incapacitated or in legal/court ordered institution - Subject has no dependency on the investigator or sponsor Exclusion Criteria: - Lack of fitness or exercise capacity to undergo bronchoscopy under general anesthesia as determined by physician prior to procedure - Acute myocardial infarction or unstable angina = 6 weeks prior to study procedure - Clinically relevant partial trachea obstruction or obstruction of vena cava per physician assessment - Acute respiratory failure, clinically significant hypoxemia, or high respiratory rate (i.e. > 30 breaths per minute) per physician assessment - Renal insufficiency that presents risk per physician's discretion or liver failure (i.e. CHILD-PUGH Class C) - World Health Organization functional Class IV Pulmonary Hypertension or history of clinically significant mPAP - Known or suspected pregnancy - Recent head injury (<12 weeks pre-procedure) or subjects presenting with clinically significant neurologic deficits - Unstable hemodynamic status (i.e. Dysrhythmia requiring intervention, altered mental status/consciousness) - Inability to adequately oxygenate subject during procedure per physicians discretion (i.e. unable to achieve S02 > 88% or requiring >4L of oxygen prior to procedure) - Subject with uncorrectable coagulopathy, bleeding or platelet disorders, history of major bleeding with bronchoscopy - Subjects contraindicated for intubation or general anesthesia, or subjects with ASA = 5 - Subjects taking antiplatelet (i.e. clopidogrel), anti-coagulant (i.e. heparin or warfarin) or /platelet aggression inhibitors (i.e. Abciximac or Eptifibatide) medications that cannot be stopped per standard practice, i.e. 5-7 days pre-procedure or heparin that cannot be held according to standard practice (6-12 hours). Aspirin not included. - Any severe or life-threatening comorbidity that could increase the risk of bronchoscopic biopsy - Moderate-to-severe pulmonary fibrosis presenting procedural risk as assessed by physician - Endobronchial lesion associated with lobar atelectasis - Known allergy, sensitivity or previous allergic reaction to ortho-phthalaldehyde (OPA) - Non-systemic treatment for lung cancer (i.e. SBRT) performed in the same lobe as the target nodule(s) - Previous surgical intervention performed in the same lobe as the target nodule (s)

Study Design


Intervention

Diagnostic Test:
Ion Endoluminal System
Robotic bronchoscopy with c-arm imaging.

Locations

Country Name City State
United States Mayo Clinic in Rochester Rochester Minnesota

Sponsors (3)

Lead Sponsor Collaborator
Mayo Clinic Intuitive Surgical, Siemens Corporation, Corporate Technology

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tool in Lesion Ability to visualize on 3D imaging the pre-planned target location characterized when displayed distance of catheter tip to nearest edge of the virtual target is = 2cm and is oriented towards the lesion in 3 axes. At the time of the procedure
Secondary Procedure-related complications Overall incidence of procedure-related complications recorded as adverse events. 6 months
Secondary Duration-related outcomes Reporting of times related to procedure times including procedure time, navigation time, time to 3D confirmation, time to tissue acquisitions, anesthesia time, and fluoroscopy time and dose. At the time of the procedure
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk